• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO

    10/26/22 7:05:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QTNT alert in real time by email

    Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer.

    Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich.

    In addition, Sannova is pleased to announce that Stephen Unger has joined the company as its new Chief Financial Officer. Mr. Unger is an accomplished finance executive with deep experience as both an operator and senior equity research analyst. He has served as CFO of Quotient Limited (NASDAQ:QTNT) and Circulogene Theranostics, Inc. and followed CROs and the life sciences tools and molecular diagnostics sectors for over 20 years at Bear Stearns, Lazard Capital Markets, and Needham & Company.

    "Jason and Steve bring new levels of client focus and operating excellence to an already stellar Sannova team," said Michael Silvon, Executive Chairman at Sannova. "Their leadership and deep sector experience fit perfectly with the Board's vision to create a multi-service CRO that builds upon a great Sannova legacy. I expect them to capitalize on our exceptional quality systems and customer-focused culture to drive us to even greater heights."

    "I am impressed with Sannova's culture and commitment to collaborate with customers to deliver high-quality services in the timeframe they require," said Mr. Apter. "I look forward to partnering with Steve, the Board, and our talented team to build on this customer experience, broaden our offering, elevate our market position, and provide greater opportunities for growth to our employees."

    "We are delighted to welcome Jason and Steve to Sannova," added Roger Freeman, Board Member at Sannova and Partner at SFW Capital Partners, the majority investor in Sannova. "Their experience driving growth at several global pharmaceutical services businesses will be tremendously valuable as Sannova continues to scale through expansion of its service offering, enhancement of its sales and marketing, and pursuit of acquisitions."

    About Sannova Analytical, LLC

    Founded in 2006, Sannova Analytical (Somerset, NJ) is a leading contract research organization that provides bioanalytical testing and analytical chemistry services for both small and large molecules to innovative pharmaceutical and biotechnology companies. Sannova is considered a trusted and quality-focused partner in drug development by customers with a strong track record of regulatory compliance. For more information, visit www.sannova.net.

    About SFW Capital Partners, LP

    SFW Capital Partners is a private equity firm focused on building market leading companies in the industrial and life sciences technology sector. SFW partners with profitable founder- and family-owned companies and provides its capital, resources, and network to make significant growth-oriented investments and drive long-term value creation. For more information, visit www.sfwcap.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005259/en/

    Get the next $QTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTNT

    DatePrice TargetRatingAnalyst
    12/3/2021$4.00 → $3.50Neutral
    Goldman Sachs
    8/6/2021$5.00 → $4.50Neutral
    Goldman Sachs
    More analyst ratings

    $QTNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO

      Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno

      10/26/22 7:05:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Appointment of New Board Member

      JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's Audit Committee. "We are delighted to welcome Mr. Aebischer to the Quotient Board," said Heino von Prondzynski, Chairman of Quotient's Board of Directors. "Thomas brings decades of experience in global financial and capital markets and a highly strategic mindset. We are very fortunate to have him by our side as we continue to grow our business and drive the value of our revolutionary diagnostic solutions.

      4/26/22 8:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Quotient Limited Announces Appointment of Chief Manufacturing Operations Officer

      JERSEY, Channel Islands, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mr. Esteban Uriarte as the Company's Chief Manufacturing Operations Officer (CMOO). Mr. Uriarte will assume the responsibilities of CMOO on February 1st, 2022. "It is my pleasure to welcome Esteban to the Executive team at this exciting time in our Company's evolution. Esteban brings his experience in leading high-growth teams and unifying manufacturing and supply chain management. As we transition the company from the development phase into commercialization, we will drive scale up in manufacturing to transform the business," said Manuel O. Mé

      11/30/21 8:30:00 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Quotient Holdings Gp, Llc claimed ownership of 17,020,000 shares

      3 - Quotient Ltd (0001596946) (Issuer)

      2/27/23 4:51:06 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 17,247,931 units of Ordinary Shares

      3 - Quotient Ltd (0001596946) (Issuer)

      2/27/23 4:05:35 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Hallsworth Frederick converted options into 438 units of Ordinary Shares, increasing direct ownership by 8% to 6,186 units

      4 - Quotient Ltd (0001596946) (Issuer)

      2/2/23 8:30:35 PM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care